Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

N. Lamichhane; Nikolaos Melas; Viktoria Bergqvist; Nils-Olof Ekholm; Ola Olén; Jonas F. Ludvigsson; Henrik Hjortswang; Jan Marsal; Carl Eriksson; Jonas Halfvarson

doi:10.1007/s10620-024-08422-9

April 18, 2024Digestive Diseases and SciencesOpen Access

Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

View Full Paper

Ask AI

Bookmark

Share

Abstract

Real-world data on starting intravenous (IV) vedolizumab (VDZ) and transitioning to subcutaneous (SC) treatment in inflammatory bowel disease (IBD) are scarce.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lamichhane et al. (2024) studied this question.

synapsesocial.com/papers/68e6e8afb6db643587663c92 https://doi.org/10.1007/s10620-024-08422-9

View Full Paper

Ask AI

Bookmark

Share

Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

Abstract

Discussion

Cite This Study

Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Digestive Diseases and Sciences

Keep reading

More related papers

More from Digestive Diseases and Sciences